Publication

Article

CURE

Fall 2008
Volume7
Issue 3

New Funding and a New Voice

New law funds pediatric cancer research.

Your tax dollars will soon be harder at work in the battle against childhood cancers.

In July, President Bush signed into law the Caroline Pryce Walker Conquer Childhood Cancer Act, legislation that increases funding for pediatric cancer research by $30 million annually for five years, beginning in 2009.

The goals of the new law include expanding biomedical research and fostering collaborative clinical trials; developing a National Institutes of Health fellowship program to encourage a new generation of scientists to focus on childhood cancers; and funding a national database to help researchers spot trends in childhood cancer rates and genetic patterns behind the diseases. The bill will also support patient and family education and access to needed treatment and support.

The legislation was named for the daughter of U.S. Rep. Deborah Pryce (R-Ohio). Caroline died almost a decade ago from neuroblastoma at age 9. Rep. Pryce, who is retiring from Congress in January, is active in childhood cancer issues and is co-founder of Hope Street Kids, which supports pediatric cancer research, advocacy, and education.

But even as Pryce retires, children with cancer will gain a new voice in Congress. In June, Rep. Joe Sestak (D-Pennsylvania) announced the establishment of a Pediatric Cancer Caucus, which he will chair. Sestak’s daughter, Alexandra, 7, is a brain cancer survivor.

Related Videos
Image of man wearing baseball cap backwards.
Dr. Emre Yekedüz highlighted strategies that may improve patients' quality of life and mitigate treatment-related side effects in renal cell carcinoma.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Image of doctor with brown hair.
Image of man with black hair.
.Dr. Catherine Wu, chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston
Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based on patient feedback.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Related Content